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Abstract
Background: The purpose of this investigation was to compare the outcome of percutaneous radiofrequency
thermal ablation therapy (PRFA) with surgical resection (SR) in the treatment of single and small hepatocellular
carcinoma (HCC).
Methods: We conducted a retrospective cohort study on 231 treatment naive patients with a single HCC ≤ 3c m
who had received either curative PRFA (162 patients) or curative SR (69 patients). All patients were regularly
followed up after treatment at our department with blood and radiologic tests.
Results: The 1-, 3- and 5-year overall survival rates after PRFA and SR were 95.4%, 79.6% and 63.1%, respectively in
the PRFA group and 100%, 81.4% and 74.6%, respectively in the SR group. The corresponding recurrence free
survival rates at 1, 3 and 5 years after PRFA and SR were 82.0%, 38.3% and 18.0%, respectively in the PRFA group
and 86.0%, 47.2% and 26.0%, respectively in the SR group. In terms of overall survival and recurrence free survival,
there were no significant differences between these two groups. In comparison of PRFA group patients with liver
cirrhosis (LC) (n = 127) and SR group patients with LC (n = 50) and in comparison of PRFA group patients without
LC (n = 35) and SR group patients without LC (n = 19), there were also no significant differences between two
groups in terms of overall survival and recurrence free survival. In the multivariate analysis of the risk factors
contributing to overall survival, serum albumin level was the sole significant factor. In the multivariate analysis of
the risk factors contributing to recurrence free survival, presence of LC was the sole significant factor. The rate of
serious adverse events in the SR group was significantly higher than that in the PRFA group (P = 0.023).
Hospitalization length in the SR group was significantly longer than in the PRFA group (P = 0.013).
Conclusions: PRFA is as effective as SR in the treatment of single and small HCC, and is less invasive than SR.
Therefore, PRFA could be a first choice for the treatment of single and small HCC.
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Background
Hepatocellular carcinoma is a major health problem
worldwide, with an estimated incidence ranging between
500,000 and 1,000,000 new cases annually. It is the fifth
most common cancer in the world and the third most
common cause of cancer-related death [1]. The
prognosis of HCC is generally poor. Surgical resection
(SR) remains the best hope for a cure but is suitable for
only 9 to 27% of patients [2,3]. The presence of signifi-
cant background liver cirrhosis (LC) often precludes
hepatic resection in patients with HCC. Recurrence in
the liver remnant is also common in patients who have
undergone radical hepatic resection.
Currently, local ablative therapy competes with surgi-
cal resection and liver transplantation as primary treat-
ment for small HCC. Various locoregional therapies are
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because of the severity of the underlying liver disease.
Percutaneous radiofrequency thermal ablation (PRFA), a
recently developed local ablative technique, has attracted
the greatest interest and popularity because of its effi-
cacy and safety [4]. Previous studies have shown PRFA
to give good results from the perspective of tumor con-
trol, with complete tumor ablation rates of 90 to 95%,
and low local tumor progression rates of 5 to 10% [5-8].
Prospective randomized trials have shown PRFA to be
better than percutaneous ethanol injection (PEI) in pro-
ducing a higher rate of complete ablation with fewer
numbers of treatment sessions [9]. However, there is
still debate with regard to whether PRFA or SR is the
most suitable therapy of small HCC.
In the present study, we conducted a retrospective
cohort study to compare the results of PRFA and SR in
the treatment of small HCC.
Methods
Patients and HCC diagnosis
Between January 2004 and January 2010, 231 patients
with single HCC ≤ 3 cm in diameter received curative
treatment using PRFA or SR in our department. Before
performing PRFA or SR, a full discussion was made
between physician and surgeon. After giving enough
information including contents of the discussion between
physician and surgeon to patients, patients themselves
made decisions whether they received PRFA or SR. In
patients with the tumor sites extremely difficult to per-
form PRFA such as the site directly under the hepatic
dome or the heart or with poor visibility of the tumor
under ultrasonography owing to extreme obesity or
impossibility of breath hold when performing PRFA, SR
was performed. And in patients whom high rates of com-
plications were expected as when tumors at the site of
hepatic hilar lesion were treated by PRFA, SR was per-
formed. In patients whom informed consent could not be
obtained upon SR for the reason such as physical burden,
PRFA was performed. Even in patients with poor liver
function such as Child-Pugh C, if they wished to treat
HCC and there were no ascites, treatment for HCC was
performed after fully explaining the risk for treatment.
PRFA was administered to 162 patients and 69 patients
underwent SR. Written informed consent was obtained
from all patients. The ethics committee of our depart-
ment approved the protocols for PRFA and SR. The pre-
sent study comprised a retrospective analysis of patient
records and all treatments were conducted in an open-
label manner. The primary end point was overall survival
and the secondary end point was recurrence free survival.
HCC was diagnosed using abdominal ultrasound and
dynamic computed tomography (CT) scans (hyperatte-
nuation during the arterial phase in all or some part of
the tumor and hypoattenuation in the portal-venous
phase) and/or magnetic resonance imaging (MRI),
mainly based on the recommendations of the Ameri-
can Association for the Study of Liver Diseases [10].
Arterial and portal phase dynamic CT images were
obtained at approximately 30 s and 120 s, respectively,
after the injection of the contrast material. Abdominal
angiography combined with CT (angio-CT) assistance
was performed on all patients before PRFA and SR.
This was due to the fact that Yamasaki et al. reported
that this technique was useful for detecting small satel-
lite nodules [11]. Then, we confirmed the presence of
single HCC ≤ 3 cm in diameter with no vascular inva-
sion using CT during hepatic arteriography (CTHA)
and arterial-portography (CTAP). With regard to the
diagnosis of liver cirrhosis, resected specimen at sur-
gery was used in the SR group, and biopsy specimen
was used in the PRFA group, respectively.
PRFA procedure
We routinely used a cool-tip needle (Radionics Corp.,
Burlington, MA, USA) while performing PRFA. Using
the intercostal or subcostal approach, a 17-gauge, 2 or
3 cm cooled-tip electrode was inserted under real-time
ultrasound guidance. The initial treatment was planned
with one ablation for tumors of < 2 cm in diameter,
and two or more ablations with the overlapping tech-
nique for tumors of ≥ 2 cm in diameter. After inser-
tion of the electrode into the tumor, we started
ablation at 60 W for the 3-cm exposed tip and 40 W
for the 2-cm exposed tip. The power was increased to
120 W at a rate of 10 W/min. The duration of a single
ablation was 12 min for the 3-cm electrode and 6 min
for the 2-cm electrode. After PRFA exposure, the
pump was stopped and the temperature of the needle
tip was measured. When the temperature reached >
60°C, additional ablation was not performed. When
tumor ablation was complete, thermal ablation was
performed along the needle track. All patients were
carefully observed for treatment-related complications.
All procedures were performed under ultrasound gui-
dance by one of five operators who had at least 3 years
of experience of performing PRFA. We used the artifi-
cial ascites technique to prevent collateral thermal
injury when the anticipated PRFA zone was in contact
with a critical organ, such as the hepatic flexure of the
colon. We also used this technique to improve visibi-
lity when the index tumor was located in the hepatic
dome area. In the present study, for all patients who
had received PRFA, we confirmed that the ablative
margin surrounded the entire circumference of the
tumor by using dynamic 16-column multi-detector CT
(MDCT) using 3-mm slice scans within 1 week after
PRFA and 1 month after PRFA.
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All procedures were performed by one of four surgeons
who had at least 10 years of experience of surgical resec-
tion. Surgical resection was carried out under general
anesthesia using a right subcostal incision with a midline
extension. We performed anatomic partial hepatectomy
with a resection margin of at least 1 cm over the tumor,
based on intraoperative ultrasonography (IOUS) gui-
dance. IOUS was routinely performed to estimate the
location, size, number and feeding vessels of the tumor,
as well as to give an exact vascular map of liver anatomy.
The Cavitron ultrasonic aspiration (CUSA, Valley Lab
Corp, USA) was used to dissect the liver tissue. Hemosta-
sis was achieved with dipolar electric coagulation and
suturing. The Pringle maneuver was usually used in case
of cirrhotic liver, with a clamp/unclamp time of 15 min/5
min policy. When liver function approached normal and
adverse events had disappeared after surgical resection,
we permitted patient discharge.
Follow-up
Follow-up consisted of monthly blood tests and monitor-
ing of tumor markers, including des-g-carboxy prothrom-
bin, which was measured using a chemiluminescent
enzyme immunoassay (Lumipulse PIVKAII Eisai, Eisai,
Tokyo, Japan). Dynamic CT scans were obtained every 3-
4 months after PRFA and SR. No patients were lost to
follow-up.
Statistical analysis
Differences between the two groups were analyzed using
the unpaired t-test for continuous variables, and the
categorical variables were analyzed using the c
2 test or
continuity correction method. The overall survival
curves and the recurrence-free survival curves were gen-
erated using the Kaplan-Meier method and compared
using the log-rank test. The relative prognostic signifi-
cance of the variables in predicting overall survival were
assessed using univariate and multivariate Cox propor-
tional hazards regression models. All variables with a P
value < 0.05 evaluated using univariate analysis were
subjected to multivariate analysis. Results of the multi-
variate analysis were presented as the hazard ratio (HR)
with a corresponding 95% confidence interval (CI). All
statistical tests were two-sided. All data were analyzed
using SPSS software, version 9.0 (SPSS Inc., Chicago, IL,
USA) for Microsoft Windows. Data are expressed as
means ± standard deviation (SD). Values of P < 0.05
were considered to be statistically significant.
Results
Patient characteristics
The baseline characteristics of the two groups are shown
i nT a b l e1 .B e t w e e nt h et w og r o u p s ,t h e r ew e r e
significant differences in tumor size (P = 0.001), platelet
count (P = 0.004) and PIVKAII value (P = 0.037).
SR group
Fifty-four of 69 patients were treated with segmentect-
omy; 12/69 patients received bisegmentectomy; 3/69
patients underwent hemihepatectomy. The histological
diagnoses of 69 patients were as follows: well-differen-
tiated hepatocellular carcinoma (3/69), moderately dif-
ferentiated hepatocellular carcinoma (36/69) and poorly
differentiated hepatocellular carcinoma (30/69). Using
dynamic CT performed within 1 month after SR, we
confirmed no residual HCC in the liver remnant of all
patients.
PRFA group
The mean number of treatment sessions for the 162
PRFA treated patients was 1.80 ± 0.37. Target biopsy
prior to PRFA was not performed on any of the patients
because of the specific complication of tumor seeding.
We confirmed that all of the PRFA treated patients
achieved complete ablation (ablated zone totally envel-
oped the tumor without enhancement) using dynamic
Table 1 Baseline characteristics of the percutaneous
radiofrequency thermal ablation (PRFA) and surgical







Male 50 95 0.054
Female 19 67
Age 67.4 ± 9.7 68.4 ± 8.7 0.45
Tumor size (cm) 2.68 ± 0.49 1.9 9 ± 0.62 0.001
Etiology of liver disease
chronic hepatitis B 8 9 0.182
chronic hepatitis C 51 135
non B, non C 10 18
Child-Pugh classification
chronic hepatitis 19 35 0.285
Child-Pugh A 45 102
Child-Pugh B 5 22
Child-Pugh C 0 3
Total-Bilirubin (mg/dL) 0.84 ± 0.48 0.93 ± 0.51 0.182
Serum albumin (g/dL) 3.89 ± 0.52 3.80 ± 0.55 0.248
Platelet ((×10
4/mm
3) 13.4 ± 6.3 11.2 ± 4.8 0.004
AST (IU/L) 58.9 ± 39.7 59.6 ± 34.0 0.897
ALT (IU/L) 53.0 ± 38.8 51.1 ± 32.7 0.697
Prothrombin time (%) 89.9 ± 14.9 87.8 ± 15.0 0.35
AFP (ng/mL) 376.7 ± 1989.8 74.7 ± 181.1 0.056
PIVKAII (mAU/mL) 739.0 ± 3900.1 95.5 ± 154.2 0.037
Data are expressed as the number of patients or the mean ± standard
deviation. AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP,
alpha-fetoprotein; PIVKAII, protein induced vitamin K absence or antagonist II
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In the present study, there were 3 patients with Child-
Pugh C who underwent PRFA. Their Child-Pugh scores
were all 10 points and PRFA was performed safely in
these 3 patients.
Patient survival
The median follow-up period was 3.1 years (0.2-7 years)
in the PRFA group and 3.3 years (0.7-7 years) in the SR
group, respectively. Thirty-three patients (20.4%) in the
PRFA group died during the follow-up period. The
causes of death were HCC recurrence (24 patients), liver
failure (6 patients) and miscellaneous (3 patients).
Twelve patients (17.4%) in the SR group died during the
follow-up period. The causes of death were HCC recur-
rence (9 patients), liver failure (2 patients) and miscella-
neous (1 patient).
The 1-, 3- and 5-year overall survival rates after PRFA
and SR were 95.4%, 79.6% and 63.1%, respectively in the
PRFA group and 100%, 81.4% and 74.6%, respectively in
the SR group (Figure 1). The corresponding recurrence
free survival rates at 1, 3 and 5 years after PRFA and SR
were 82.0%, 38.3% and 18.0%, respectively in the PRFA
group and 86.0%, 47.2% and 26.0%, respectively in the
SR group (Figure 2).
In terms of overall survival (P = 0.259) and recurrence
free survival (P = 0.324), there were no significant differ-
ences between these two groups.
Figure 1 Cumulative overall survival rate. The 1-, 3- and 5-year overall survival rates after percutaneous radiofrequency thermal ablation
(PRFA) and surgical resection (SR) were 95.4%, 79.6% and 63.1%, respectively in the PRFA group and 100%, 81.4% and 74.6%, respectively in the
SR group. There was no significant difference between these two groups as determined using the log-rank test (P = 0.259).
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We defined local tumor progression as the presence of a
hypervascular nodule adjacent to the ablated area of
PRFA or the resected area of SR using dynamic CT scan.
20 patients in the PRFA group and 10 patients in the SR
group had local tumor progression during the observa-
tion period. The 1-, 3- and 5-year local tumor progres-
sion rates after PRFA and SR were 2.0%, 14.3% and
28.3%, respectively in the PRFA group and 2.8%, 14.3%
and 22.8%, respectively in the SR group. (Figure 3) In
terms of local tumor progression, there was no significant
difference between these two groups (P = 0.746).
Comparison between PRFA group patients with LC and
SR group patients with LC
There were 127 patients in PRFA group patients with LC
and 50 patients in SR group patients with LC,
respectively. The 1-, 3- and 5-year overall survival rates
after PRFA and SR were 94.2%, 75.8% and 56.4%, respec-
tively in the PRFA group with LC and 100%, 78.0% and
67.8%, respectively in the SR group with LC. (Figure 4)
The corresponding recurrence free survival rates at 1, 3
and 5 years after PRFA and SR were 86.0%, 35.0% and
14.8%, respectively in the PRFA group with LC and
79.5%, 39.3% and 23.8%, respectively in the SR group
with LC. (Figure 5) In terms of overall survival (P =
0.521) and recurrence free survival (P = 0.669), there
were no significant differences between these two groups.
Comparison between PRFA group patients without LC
and SR group patients without LC
There were 35 patients in PRFA group patients without
LC and 19 patients in SR group patients without LC,
respectively. The 1-, 3- and 5-year overall survival rates
Figure 2 Cumulative recurrence free survival rate. The 1-, 3- and 5-year recurrence free survival rates after percutaneous radiofrequency
thermal ablation (PRFA) and surgical resection (SR) were 82.0%, 38.3% and 18.0%, respectively in the PRFA group and 86.0%, 47.2% and 26.0%,
respectively in the SR group There was no significant differences between these two groups as determined using the log-rank test (P = 0.324).
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tively in the PRFA group without LC and 100%, 95.6% and
95.6%, respectively in the SR group without LC. (Figure 6)
The corresponding recurrence free survival rates at 1, 3
and 5 years after PRFA and SR were 93.0%, 52.5% and
22.2%, respectively in the PRFA group with LC and 100%,
75.7% and 30.4%, respectively in the SR group with LC.
( F i g u r e7 )I nt e r m so fo v e r a l ls u r v i v a l( P=0 . 2 7 6 )a n d
recurrence free survival (P = 0.258), there were no signifi-
cant differences between these two groups.
Serious adverse events, hospitalization length and
mortality
Serious adverse events were significantly more frequent
in the SR group than in the PRFA group (6/69 versus 3/
162; P = 0.023). Serious adverse events in the SR group
were as follows: bile leakage (2 patients); refractory
ascites (2 patients); acute respiratory distress syndrome
(ARDS) (1 patient); and massive gastrointestinal bleeding
(1 patient). Serious adverse events in the PRFA group
were as follows: biloma (1 patient); refractory ascites (1
patient); and intra-abdominal bleeding (1 patient).
The hospitalization length was significantly longer in
the SR group (18.1 ± 10.4 days) than in the PRFA group
(14.7 ± 5.7 days) (P = 0.013). In addition, there was no
patient who died within the same hospitalization, mak-
ing the mortality rate 0% in two groups.
Univariate and multivariate analysis of prognostic factors
contributing to overall survival and recurrence free
survival
In the univariate analysis of factors contributing to overall
survival, hepatitis C virus (HCV) versus non HCV (P =
0.042), serum albumin (g/dL) (> 3.5 versus ≤ 3.5) (P =
Figure 3 Cumulative local tumor progression rate. The 1-, 3- and 5-year local tumor progression rates after percutaneous radiofrequency
thermal ablation (PRFA) and surgical resection (SR) were 2.0%, 14.3% and 28.3%, respectively in the PRFA group and 2.8%, 14.3% and 22.8%,
respectively in the SR group. There was no significant differences between these two groups as determined using the log-rank test (P = 0.746).
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4/mm
3) (> 10 versus ≤ 10)
(P = 0.045) were found to be significant factors (Table 2).
However, in the multivariate analyses involving these three
factors, serum albumin (g/dL) (> 3.5 versus ≤ 3.5) was the
sole significant factor contributing to overall survival.
Similarly, in the univariate analysis of factors contri-
buting to recurrence free survival, HCV versus non
HCV (P = 0.022), LC versus non LC (P = 0.002) and
platelet count (× 10
4/mm
3)( >1 0v e r s u s≤ 10) (P =
0.005) were found to be significant factors (Table 3).
However, in the multivariate analyses involving these
three factors, the presence of LC was the sole significant
factor contributing to recurrence free survival.
Discussion
Partial hepatectomy in patients with resectable HCC,
who have normal liver function and are in good general
condition is still considered the gold standard therapy
with the aim of delivering curability [12]. In recent
years, it has been possible to reduce perioperative mor-
tality to less than 5% depending on the extent of resec-
tion and hepatic reserve [13]. The improved outcome is
primarily as a result of advances in surgical and radiolo-
gic techniques, perioperative care and more cautious
patient selection [14].
Patients not eligible for resection because of their
medical condition might be candidates for local ablative
therapy, such as percutaneous ethanol injection (PEI)
and PRFA. Many clinical trials comparing PRFA and
PEI have demonstrated the clear superiority of PRFA
over PEI [9,15-17]. However, a major limitation of PRFA
is the small volume of tumor that can be treated. The
rate of complete ablative necrosis decreases with the
size of the tumor, particularly in the case of tumors
Figure 4 Cumulative overall survival rate between percutaneous radiofrequency thermal ablation (PRFA) group patients with liver
cirrhosis (LC) (n = 127) and surgical resection (SR) group patients with liver cirrhosis (LC) (n = 50). The 1-, 3- and 5-year overall survival
rates after PRFA and SR were 94.2%, 75.8% and 56.4%, respectively in the PRFA group with LC and 100%, 78.0% and 67.8%, respectively in the SR
group with LC. There was no significant differences between these two groups as determined using the log-rank test (P = 0.521).
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plete response to PRFA therapy in patients is associated
with improved outcome [18-20]. Therefore, in the pre-
sent study, objectives were limited to patients with HCC
≤ 3 cm in size.
HCC mainly disseminatest h r o u g ht h ep o r t a la n d
hepatic veins. The micro-dissemination can invade the
tributaries of the portal branches and shed tumor
emboli in the neighboring branches of the same liver
segment [21-24]. However, in the present study, with
regard to recurrence free survival, there was no signifi-
cant difference between the two treatment groups. One
possible reason for this is that a sufficient ablative
margin around the tumor when PRFA is administered
may suppress the invasion of the micro-dissemination.
Previous studies have reported that the initial treatment
contributes to the survival of HCC patients treated
using PRFA [19,25]. In PRFA therapy, obtaining suffi-
cient ablative margin around the tumor seems to be
essential.
The findings of the present study indicated that the
overall and recurrence free survivals were the same for
patients with a single HCC ≤ 3 cm in diameter treated
with either PRFA or SR. In addition, PRFA was demon-
strated to have an advantage over SR in causing less ser-
ious adverse events and a shorter hospitalization length.
Figure 5 Cumulative recurrence free survival rate between percutaneous radiofrequency thermal ablation (PRFA) group patients with
liver cirrhosis (LC) (n = 127) and surgical resection (SR) group patients with liver cirrhosis (LC) (n = 50). The 1-, 3- and 5-year recurrence
free survival rates after PRFA and SR were 86.0%, 35.0% and 14.8%, respectively in the PRFA group with LC and 79.5%, 39.3% and 23.8%,
respectively in the SR group with LC. There was no significant differences between these two groups as determined using the log-rank test (P =
0.669).
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on 180 patients with a single HCC ≤ 5 cm to receive
either PRFA or surgical resection [12], and Lu et al car-
ried out another RCT on 105 patients with early HCC
[26]. These two RCTs presented similar findings to
those of our study. Additionally, four non-randomized
controlled studies also reported similar findings of ours
[27-30]. And our study suggests that PRFA is less inva-
sive than SR. It seems that PRFA can be a first choice
for the treatment of small HCC. On the other hand, a
recent study indicated that surgical resection provided
better survival and lower recurrence rates than RFA for
patients with HCC that conformed to the Milan criteria
for a RCT [31]. However, in comparing their results
with ours, the mean age of their patient population was
more than 10 years younger than ours. In the etiology
of liver disease in their study, patients with chronic
hepatitis B were in the majority [31]. However, in our
study, patients with chronic hepatitis C were in the
majority. Therefore, their study results did not reflect
the actual situation in Japan where Japanese HCC
patients consist of many elderly patients, and the etiol-
ogy of background liver disease involves chronic hepati-
tis C which accounts for about 80% of Japanese HCC
patients. Hence, we should interpret their study results
with caution.
Our study had several limitations. First, it was a retro-
spective cohort study. Patients who had a good hepatic
reserve tended to receive surgical resection, and this
could have possibly led to bias. Second, we did not
assess the histopathologic diagnosis of HCC in the
PRFA group. Tateishi et al reported that patients with
Figure 6 Cumulative overall survival rate between percutaneous radiofrequency thermal ablation (PRFA) group patients without liver
cirrhosis (LC) (n = 35) and surgical resection (SR) group patients without liver cirrhosis (LC) (n = 19). The 1-, 3- and 5-year overall survival
rates after PRFA and SR were 96.6%, 87.2% and 74.4%, respectively in the PRFA group without LC and 100%, 95.6% and 95.6%, respectively in the
SR group without LC. There was no significant differences between these two groups as determined using the log-rank test (P = 0.276).
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Page 9 of 12Figure 7 Cumulative recurrence free survival rate between percutaneous radiofrequency thermal ablation (PRFA) group patients
without liver cirrhosis (LC) (n = 35) and surgical resection (SR) group patients without liver cirrhosis (LC) (n = 19). The 1-, 3- and 5-year
recurrence free survival rates after PRFA and SR were 93.0%, 52.5% and 22.2%, respectively in the PRFA group without LC and 100%, 75.7% and
30.4%, respectively in the SR group without LC. There was no significant differences between these two groups as determined using the log-
rank test (P = 0.258).




Hazard Ratio (95%CI) P value
Surgical resection vs PRFA 0.257 0.964(0.870-1.224) 0.889
Gender (male vs female) 0.811
Age (> 65 vs ≤ 65) 0.639
HBV vs non HBV 0.074
HCV vs non HCV 0.042 0.516 (0.163-1.628) 0.259
LC vs non LC 0.073
Albumin (g/dL) (> 3.5 vs ≤ 3.5) 0.003 1.732 (1.015-3.314) 0.047
T-Bil (mg/dL) (> 1.0 vs ≤ 1.0) 0.141
Platelet (×10
4/mm
3)( >1 0v s≤ 10) 0.045 1.132 (0.568-2.258) 0.724
Prothrombin time (%) (> 80 vs ≤ 80) 0.068
Serum AFP (> 100 vs ≤ 100) 0.987
PIVKAII (> 100 vs ≤ 100) 0.15
Tumor size (cm) (> 2 vs ≤ 2) 0.883
PRFA, percutaneous radiofrequency thermal ablation; HBV, hepatitis B virus; HCV, hepatitis C virus; LC, liver cirrhosis; T-Bil, total bilirubin; CI, confidence interval;
AFP, alpha-fetoprotein; PIVKAII, protein induced vitamin K absence or antagonist II
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patients with well to moderately differentiated HCC
after PRFA [32]. Third, our study patients were limited
to patients who have undergone curative treatment.
These problems should be resolved in a future prospec-
tive study.
Conclusion
In conclusion, we demonstrated that PRFA is as effective
as SR in the treatment of single and small HCC patients
who have undergone curative treatment, and that PRFA
is less invasive than SR. Therefore, PRFA can be a first
choice for the treatment of single and small HCC.
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